Impact of Cell of Origin, MYC/BCL2 Dual Expression and MYC Rearrangements in Diffuse Large B-Cell Lymphoma Patients Treated with Combined Modality Therapy

Augustyn A.; Gunther J. R.; Medeiros L. J.; Milgrom S. A.; Nastoupil L.; Neelapu S. S.; Nair R.; Li S.; Ok C. Y.; Steiner R. E.; Iyer S. P.; Ahmed S.; Westin J.; Rodriguez M. A.; Pasalic D.; Fayad L.; Samaniego F.; Dabaja B.; Pinnix C. C.

首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Impact of Cell of Origin, MYC/BCL2 Dual Expression and MYC Rearrangements in Diffuse Large B-Cell Lymphoma Patients Treated with Combined Modality Therapy

【24h】

Impact of Cell of Origin, MYC/BCL2 Dual Expression and MYC Rearrangements in Diffuse Large B-Cell Lymphoma Patients Treated with Combined Modality Therapy

机译：弥漫性大型B细胞淋巴瘤患者血小态疗效治疗的弥漫性大B细胞淋巴瘤患者的影响，MYC / BCL2双重表达和MYC重排的影响

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《International Journal of Radiation Oncology, Biology, Physics》 |2019年第1suppla期|共1页
作者
Augustyn A.; Gunther J. R.; Medeiros L. J.; Milgrom S. A.; Nastoupil L.; Neelapu S. S.; Nair R.; Li S.; Ok C. Y.; Steiner R. E.; Iyer S. P.; Ahmed S.; Westin J.; Rodriguez M. A.; Pasalic D.; Fayad L.; Samaniego F.; Dabaja B.; Pinnix C. C.;
展开▼
作者单位

Univ Texas MD Anderson Canc Ctr Div Radiat Oncol Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Div Radiat Oncol Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Hematopathol Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Div Radiat Oncol Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma &

Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma &

Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma &

Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Hematopathol Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Hematopathol Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma &

Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma &

Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma &

Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma &

Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma &

Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Div Radiat Oncol Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma &

Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma &

Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Div Radiat Oncol Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类放射医学;
关键词

相似文献

外文文献
中文文献
专利

1. Impact of Cell of Origin, MYC/BCL2 Dual Expression and MYC Rearrangements in Diffuse Large B-Cell Lymphoma Patients Treated with Combined Modality Therapy [J] . Augustyn A., Gunther J. R., Medeiros L. J., International Journal of Radiation Oncology, Biology, Physics . 2019,第1Suppla期

机译：弥漫性大型B细胞淋巴瘤患者血小态疗效治疗的弥漫性大B细胞淋巴瘤患者的影响，MYC / BCL2双重表达和MYC重排的影响
2. MYC MYC rearrangement and MYC/BCL2 double expression but not cell‐of‐origin predict prognosis in R‐CHOP?treated diffuse large B‐cell lymphoma [J] . Xu Jie, Liu Jing‐Lan, Medeiros L. Jeffrey, European Journal of Haematology . 2020,第4期

机译：Myc Myc重排和Myc / Bcl2双表达，但不是原产地预测R-Check中的预后？处理的弥漫性大B细胞淋巴瘤
3. Clinical Impact of the Cell-of-Origin Classification and the MYC/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group [J] . Staiger Annette M., Ziepert Marita, Horn Heike, Journal of Clinical Oncology . 2017,第22期

机译：德国高级非霍奇金淋巴瘤研究组前瞻性临床试验中弥漫性大B细胞淋巴瘤在弥漫性大B细胞淋巴瘤中的临床影响和MYC / BCL2双重患者的临床影响
4. Predicting MYC translocation in HE specimens of diffuse large B-cell lymphoma through deep learning [C] . Zaneta Swiderska-Chadaj, Konnie Hebeda, Michiel van den Brand, Conference on Medical Imaging: Digital Pathology . 2020

机译：通过深度学习预测弥漫性大B细胞淋巴瘤标本的MYC易位
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Clinical Significance of BCL2 C-MYC and BCL6 Genetic Abnormalities Epstein-Barr Virus Infection CD5 Protein Expression Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients [O] . Choo-Yuen Ting, Kian-Meng Chang, Jew-Win Kuan, 2019

机译：BCL2C-MYC和BCL6遗传异常爱泼斯坦-巴尔病毒感染CD5蛋白表达生发中心B细胞/非生发中心B细胞亚型MYC / BCL2蛋白的共表达和共表达的临床意义弥漫性大B细胞淋巴瘤中MYC / BCL2 / BCL6蛋白的表达：120例患者的临床和病理相关性研究
7. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma [O] . Xuan J Wang, L Jeffrey Medeiros, Carlos E Bueso-Ramos, 2016

机译：P53表达与较差的存活率相关，增强Myc重排，表达或同时Myc / Bcl2表达在弥漫性大B细胞淋巴瘤中的负预测效果

Impact of Cell of Origin, MYC/BCL2 Dual Expression and MYC Rearrangements in Diffuse Large B-Cell Lymphoma Patients Treated with Combined Modality Therapy

著录项

相似文献

相关主题

期刊订阅